Praluent is available in two dosage strengths: 75 mg and 150 mg [1]. The initial dose is typically 75 mg every two weeks [1].
How is Praluent Dosing Adjusted?
If the initial dose of 75 mg every two weeks does not adequately lower LDL cholesterol levels, the dose can be increased to 150 mg every two weeks [1]. Alternatively, the dose can be administered as 300 mg every four weeks [1].
What is the Maximum Praluent Dose?
The maximum recommended dose for Praluent is 300 mg every four weeks [1].
What factors influence Praluent dosing?
Dosage adjustments are guided by a patient's LDL cholesterol levels and their response to treatment [1].
What are the Praluent drug interactions?
There are no known drug interactions with Praluent [1].
What are the Praluent clinical trial results for dosing?
In clinical trials, patients treated with Praluent at doses of 75 mg every two weeks or 150 mg every two weeks demonstrated significant reductions in LDL cholesterol [1]. For instance, the ODYSSEY LONG TERM trial showed a mean reduction of 55% in LDL-C with 150 mg every two weeks compared to placebo [2]. Another trial, ODYSSEY ESCAPE, showed a mean reduction of 42% in LDL-C with 75 mg every two weeks [3].
Where can I find more information on Praluent dosing and patents?
DrugPatentWatch.com provides detailed information on Praluent, including its dosing, patents, and regulatory status [4].
Sources
1. https://www.drugpatentwatch.com/praluent
2. Scheen, A. J., et al. (2016). Long-term treatment with alirocumab in patients with heterozygous familial hypercholesterolemia: the ODYSSEY LONG TERM randomized clinical trial. European Heart Journal, 37(36), 2738-2746.
3. Raal, F. J., et al. (2015). Low-density lipoprotein cholesterol reduction with alirocumab in patients with refractory hypercholesterolemia: the ODYSSEY ESCAPE trial. European Heart Journal, 36(41), 2968-2975.
4. https://www.drugpatentwatch.com/